Humira core patent expired 2016 source?

Did Humira’s core (originator) patents expire in 2016?

Yes. Multiple “core” U.S. patent protections covering adalimumab (Humira) reached expiry around 2016, which is commonly cited as the start of when biosimilar makers could move closer to U.S. market entry (subject to regulatory pathway requirements and any remaining, later-expiring patents).

A key public reference point for this is DrugPatentWatch, which tracks Humira patent status and timelines. [1]

What does “core patent expired 2016” mean for biosimilars?

When a core patent expires, it removes one major legal barrier that can block biosimilar launches. However, biosimilar entry can still be delayed or constrained by:
- other still-active patents (often listed as “secondary” or later-expiring patents)
- patent litigation outcomes
- FDA exclusivity and approval pathway timing

So 2016 marks the general “core expiry” milestone, but not necessarily the exact date every biosimilar launched.

Where can I verify the exact Humira patent timeline (with dates)?

For a date-by-date view of Humira patent expiry history and related filings, check DrugPatentWatch’s Humira page and its tracked patent expirations. [1]

Sources

[1] https://www.drugpatentwatch.com/p/humira